Department of Hematology, Shanxi Tumor Hospital, #3, xinjie west avenue, 030013 Xinghualing District, Taiyuan, Shanxi, People's Republic of China.
Med Oncol. 2011 Dec;28 Suppl 1:S367-72. doi: 10.1007/s12032-010-9756-0. Epub 2010 Dec 3.
To analyze the clinical characteristics, treatment of extranodal NK/T-cell lymphoma, nasal type, the term "nasal type" describes in the nasal cavity and also in the extranasal sites. There were 82 patients with nasal NK/T lymphoma (group 1) and 11 patients with extranasal NK/T lymphoma (group 2). In group 1, 4 patients gave up treatment. Five patients received radiotherapy (RT) alone. Fifty-seven patients were treated with combination of chemotherapy and RT. Sixteen patients received chemotherapy alone. Most patients (82.9%) had stage I/II disease and a high frequency (about one-third) of B symptoms. The CR rate was 53.8%. The OS rate was 62.8% (49/78 cases). Three patients died in relation to L-asparaginase. Three patients with late relapses occurred at 10 and 17 years from CR, respectively. In group 2, except that one patient received chemoradiotherapy, 10 patients received chemotherapy. Seven patients died. The OS rate was 36.4%. Our study suggested that nasal and extranasal variants of extranodal NK/T lymphoma, nasal type represented different clinical behavior and prognosis. For comparison, extranasal NK/T lymphoma is more aggressive and higher mortality than nasal NK/T lymphoma.
为分析结外 NK/T 细胞淋巴瘤，鼻型的临床特征和治疗方法，“鼻型”一词既描述了鼻腔内，也描述了鼻腔外的病变部位。共有 82 例鼻腔 NK/T 淋巴瘤患者（第 1 组）和 11 例鼻腔外 NK/T 淋巴瘤患者（第 2 组）。第 1 组中，4 例患者放弃治疗，5 例接受单纯放疗，57 例接受化疗联合放疗，16 例接受单纯化疗。大多数患者（82.9%）为Ⅰ/Ⅱ期疾病，且约三分之一存在 B 症状。完全缓解率为 53.8%，总生存率为 62.8%（78 例中的 49 例）。有 3 例患者死于左旋门冬酰胺酶相关毒性，3 例患者分别在缓解后 10 年和 17 年复发。第 2 组中，除 1 例患者接受放化疗外，其余 10 例患者接受化疗，7 例死亡，总生存率为 36.4%。本研究表明，鼻腔型和鼻腔外型结外 NK/T 细胞淋巴瘤具有不同的临床行为和预后。相比之下，鼻腔外 NK/T 淋巴瘤比鼻腔 NK/T 淋巴瘤侵袭性更强，死亡率更高。
